Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alpharma’s Embeda Has “Incremental Benefit” In Reducing Opioid Abuse, FDA Cmte. Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory committee expresses concern over variability in benefit seen among patients; many still experience euphoria sought by opioid abusers.

You may also be interested in...



Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning

Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins

Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning

Opioid products awaiting FDA approval are not being put on hold for completion of a Risk Evaluation and Mitigation Strategy, said Office of New Drugs Director John Jenkins

Pain Therapeutics’ Remoxy Is More Abuse-Resistant Than Other Oxycodone Formulations, FDA Panel Suggests

Approval may depend on FDA’s confidence that the firm’s proposed REMS can adequately monitor for abuse – a subject of apparent debate within FDA.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel